Publications
Found 17 results
Filters: Keyword is Trypanosomiasis, African and Author is Benoît Stijlemans [Clear All Filters]
"Antibody-mediated control of Trypanosoma vivax infection fails in the absence of tumour necrosis factor.",
Parasite Immunol, vol. 36, issue 6, pp. 271-6, 2014 Jun.
"Using microdialysis to analyse the passage of monovalent nanobodies through the blood-brain barrier.",
Br J Pharmacol, vol. 165, issue 7, pp. 2341-53, 2012 Apr.
"High affinity nanobodies against the Trypanosome brucei VSG are potent trypanolytic agents that block endocytosis.",
PLoS Pathog, vol. 7, issue 6, pp. e1002072, 2011 Jun.
"The central role of macrophages in trypanosomiasis-associated anemia: rationale for therapeutical approaches.",
Endocr Metab Immune Disord Drug Targets, vol. 10, issue 1, pp. 71-82, 2010 Mar.
"Current status of vaccination against African trypanosomiasis.",
Parasitology, vol. 137, issue 14, pp. 2017-27, 2010 Dec.
"Scrutinizing the mechanisms underlying the induction of anemia of inflammation through GPI-mediated modulation of macrophage activation in a model of African trypanosomiasis.",
Microbes Infect, vol. 12, issue 5, pp. 389-99, 2010 May.
"Role of iron homeostasis in trypanosomiasis-associated anemia.",
Immunobiology, vol. 213, issue 9-10, pp. 823-35, 2008.
"African trypanosomosis: from immune escape and immunopathology to immune intervention.",
Vet Parasitol, vol. 148, issue 1, pp. 3-13, 2007 Aug 19.
"A glycosylphosphatidylinositol-based treatment alleviates trypanosomiasis-associated immunopathology.",
J Immunol, vol. 179, issue 6, pp. 4003-14, 2007 Sep 15.
"Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor.",
Nat Med, vol. 12, issue 5, pp. 580-4, 2006 May.
"[Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor].",
Med Sci (Paris), vol. 22, issue 11, pp. 914-6, 2006 Nov.
"Tsetse fly saliva accelerates the onset of Trypanosoma brucei infection in a mouse model associated with a reduced host inflammatory response.",
Infect Immun, vol. 74, issue 11, pp. 6324-30, 2006 Nov.
"The induction of a type 1 immune response following a Trypanosoma brucei infection is MyD88 dependent.",
J Immunol, vol. 175, issue 4, pp. 2501-9, 2005 Aug 15.
"P75 tumor necrosis factor-receptor shedding occurs as a protective host response during African trypanosomiasis.",
J Infect Dis, vol. 189, issue 3, pp. 527-39, 2004 Feb 1.
"Control of experimental Trypanosoma brucei infections occurs independently of lymphotoxin-alpha induction.",
Infect Immun, vol. 70, issue 3, pp. 1342-51, 2002 Mar.
"Comparative analysis of antibody responses against HSP60, invariant surface glycoprotein 70, and variant surface glycoprotein reveals a complex antigen-specific pattern of immunoglobulin isotype switching during infection by Trypanosoma brucei.",
Infect Immun, vol. 68, issue 2, pp. 848-60, 2000 Feb.
"The glycosyl-inositol-phosphate and dimyristoylglycerol moieties of the glycosylphosphatidylinositol anchor of the trypanosome variant-specific surface glycoprotein are distinct macrophage-activating factors.",
J Immunol, vol. 160, issue 4, pp. 1949-56, 1998 Feb 15.